Huls, G. A., Kühn, M. W. M., Vyas, P., Döhner, H., Lowenberg, B., Gradowska, P., Price, S., Smith, A. R., Botton, S. D., Récher, C., Esteve, J., Venditti, A., Pabst, T., Lazarevic, V., Porkka, K., Breems, D., Zucenka, A., Koller, E., Wei, A. H., Zeidner, J. F. (2026). A phase 3 study of revumenib plus venetoclax/azacitidine in adults with newly diagnosed NPM1 -mutated or KMT2A -rearranged acute myeloid leukemia ineligible for intensive chemotherapy (EVOLVE-2/HO177/AMLSG35-24/ACT-HOV-AML-002).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.tps6600